These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34409904)

  • 21. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
    Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
    J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué-Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD010783. PubMed ID: 34313331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans.
    Julayanont P; DeToledo JC
    J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mini-Mental State Examination and Montreal Cognitive Assessment as Tools for Following Cognitive Changes in Alzheimer's Disease Neuroimaging Initiative Participants.
    Wang G; Estrella A; Hakim O; Milazzo P; Patel S; Pintagro C; Li D; Zhao R; Vance DE; Li W;
    J Alzheimers Dis; 2022; 90(1):263-270. PubMed ID: 36093696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
    Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
    Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.
    Benoit JS; Chan W; Piller L; Doody R
    Am J Alzheimers Dis Other Demen; 2020; 35():1533317520918719. PubMed ID: 32573256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué I Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010783. PubMed ID: 25740785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-Administered Gerocognitive Examination: longitudinal cohort testing for the early detection of dementia conversion.
    Scharre DW; Chang SI; Nagaraja HN; Wheeler NC; Kataki M
    Alzheimers Res Ther; 2021 Dec; 13(1):192. PubMed ID: 34872596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Crane PK; Carle A; Gibbons LE; Insel P; Mackin RS; Gross A; Jones RN; Mukherjee S; Curtis SM; Harvey D; Weiner M; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):502-16. PubMed ID: 22782295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.
    Karcher H; Savelieva M; Qi L; Hummel N; Caputo A; Risson V; Capkun G; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2020; 17(7):635-657. PubMed ID: 33032508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
    Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
    J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
    Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
    Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.